- Home
- AUPH vs CDRE Comparison
AUPH vs CDRE Comparison
Compare AUPH & CDRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- CDRE
- Stock Information
- Founded
- AUPH 1993
- CDRE 2012
- Country
- AUPH Canada
- CDRE United States
- Employees
- AUPH N/A
- CDRE 2284
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- CDRE Industrial Specialties
- Sector
- AUPH Health Care
- CDRE Health Care
- Exchange
- AUPH Nasdaq
- CDRE Nasdaq
- Market Cap
- AUPH 1.6B
- CDRE 1.8B
- IPO Year
- AUPH 1999
- CDRE 2021
- Fundamental
- Price
- AUPH $16.44
- CDRE $43.45
- Analyst Decision
- AUPH Strong Buy
- CDRE Buy
- Analyst Count
- AUPH 3
- CDRE 2
- Target Price
- AUPH $17.67
- CDRE $34.50
- AVG Volume (30 Days)
- AUPH 2.2M
- CDRE 309.7K
- Earning Date
- AUPH 11-04-2025
- CDRE 11-04-2025
- Dividend Yield
- AUPH N/A
- CDRE 0.87%
- EPS Growth
- AUPH N/A
- CDRE 33.82
- EPS
- AUPH 0.55
- CDRE 1.11
- Revenue
- AUPH $265,808,000.00
- CDRE $619,068,000.00
- Revenue This Year
- AUPH $17.33
- CDRE $12.55
- Revenue Next Year
- AUPH $14.31
- CDRE $7.70
- P/E Ratio
- AUPH $29.89
- CDRE $39.34
- Revenue Growth
- AUPH 20.62
- CDRE 19.94
- 52 Week Low
- AUPH $6.55
- CDRE $27.07
- 52 Week High
- AUPH $16.47
- CDRE $46.64
- Technical
- Relative Strength Index (RSI)
- AUPH 75.78
- CDRE 59.91
- Support Level
- AUPH $14.94
- CDRE $38.94
- Resistance Level
- AUPH $15.81
- CDRE $41.64
- Average True Range (ATR)
- AUPH 0.61
- CDRE 1.50
- MACD
- AUPH 0.06
- CDRE -0.22
- Stochastic Oscillator
- AUPH 97.97
- CDRE 81.00
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.